Sign In
5 Oct 2020 07:00
5 October 2020
ABCAM PLC
("Abcam" or "the Company")
Directorate Change
On 16 June 2020, Abcam plc announced that Jonathan Milner, co-founder and Non-Executive Deputy Chairman of Abcam, had informed the Board that he would be standing down from the Board in due course, to allow him to focus on his growing portfolio of early stage company investments.
Further to that announcement, Abcam announces that Jonathan has today stepped down from the Board.
Alan Hirzel, Chief Executive Officer of Abcam, said:
"I thank Jonathan for his extraordinary vision and determination in creating Abcam in 1998. His early dedication to leading the business in the early years and his later role on the board, helped Abcam achieve its leadership position today. I wish him continued success as he nurtures other life sciences companies through stages of growth."
Peter Allen, Chairman of Abcam, added:
"On behalf of the Board and all at Abcam, I wish to join Alan in thanking Jonathan for his exceptional dedication to creating a multi billion pound business from humble beginnings. I and all the team wish him every success in the future."
Jonathan Milner, Non-Executive Deputy Chairman of Abcam, commented:
"I am very proud that Abcam has flourished and become such a significant global business over the last two decades. I believe that the business is in very strong hands with an exciting growth strategy. I thank everyone past and present for contributing to this success story. I remain a significant shareholder and supporter of the business and look forward to seeing it grow to the next level."
For further information, please contact:
Abcam | + 44 (0) 1223 696 000 |
James Staveley, Vice President, Investor Relations | |
Numis - Nominated Advisor & Joint Corporate Broker | + 44 (0) 20 7260 1000 |
Garry Levin / Duncan Monteith / Huw Jeremy | |
J.P. Morgan Cazenove - Joint Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Hemant Kapoor | |
Morgan Stanley - Joint Corporate Broker | + 44 (0) 207 425 8000 |
Tom Perry / Luka Kezic | |
FTI Consulting | + 44 (0) 20 3727 1000 |
Ben Atwell / Natalie Garland-Collins |
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Some two-thirds of the world's 750,000 life science researchers use Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 140 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
Please visit www.abcam.com or www.abcamplc.com to find out more.
Follow the stocks
